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The reasons for enhanced deposition of extracellular matrix in the airways of asthmatic
patients and the subsequent consequences on lung function are uncertain. Here, we investi-
gated the synthesis of procollagen I and proteoglycans, the activity of various metalloprotei-
nases (MMPs) and the production of their inhibitor TIMP-1 in biopsy-derived bronchial
fibroblasts from eight patients with stable mild-to-moderate asthma, and how they are related
to patients’ lung function and airway hyperreactivity (AHR).
Following 24-h fibroblast incubation in 0.4% serum, procollagen I carboxyterminal propep-
tide (PICP), TIMP-1 and MMP-1 in cell media were analysed by ELISA, MMP-2, MMP-3, MMP-9
by zymography and total proteoglycan production by [35S]-sulphate-incorporation/ion chroma-
tography.
Patients’ FEV1% predicted and methacholine log PD20 negatively correlated with PICP
synthesized by patients’ bronchial fibroblasts (r Z 0.74 and r Z 0.71, respectively). PICP
and proteoglycan amounts positively correlated (0.8  r  0.9) with MMP-2 and MMP-3 activity.
A positive correlation (rZ 0.75) was also found between proteoglycan production and TIMP-1.
There was no correlation between MMP-9 activity and PICP or proteoglycan production. MMP-9
activity positively correlated with patients’ FEV1% predicted (r Z 0.97) and methacholine log
PD20 (rZ 0.86), whereas negative associations (0.6  r  0.7) were observed for MMP-2 and
MMP-3.
In stable mild-to-moderate asthma, increased procollagen I synthesis and activity of MMP-2
and MMP-3 in bronchial fibroblasts may negatively affect patients’ lung function and AHR.222 33 14; fax: þ46 46 211 34 17.
n-Thorsson@med.lu.se (G. W. Thorsson).
0 Elsevier Ltd. All rights reserved.
1800 L. Todorova et al.In contrast, MMP-9 activity was not associated with procollagen or proteoglycan production, or
worsening of patients’ lung function and AHR. An enhanced production of procollagen I and
proteoglycans might be a result of a negative feedback from their degradation by MMP-2
and MMP-3.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
A prominent feature of airway remodeling in asthma is
enhanced deposition of extracellular matrix (ECM)
throughout the airway wall. Increased concentration of
various collagens, proteoglycans and fibronectin are
observed in the subepithelial lamina reticularis, in the
deeper submucosa area and around the smooth muscle
layer (reviewed in Ref.1). Such structural changes occur
early in asthmatic children and may be responsible for the
greatest loss of lung function early in the course of
asthma.2
Increased deposition of ECM is determined by synthesis
of ECM components and their degradation. Fibroblasts are
the main cells responsible for ECM production and turnover
in the airways and lung tissue although other resident cells,
such as airway epithelial cells and smooth muscle cells may
be involved.3,4 A greater number of fibroblasts were found
in the submucosal layer of the airways of asthmatic
patients than in healthy subjects,5 and the increased
number of fibroblasts also correlated to thickening of the
subepithelial basement membrane.6 The main enzymes
responsible for ECM degradation are the matrix metal-
loproteinases (MMPs), which are produced by lung fibro-
blasts and target almost all components of the ECM.7
Paradoxically, along with the increased ECM deposition in
the airways of asthmatic patients, the concentration and
activity of various MMPs are also enhanced compared with
healthy subjects. The major MMPs increased in the airways
of asthmatic patients are gelatinases MMP-9 and MMP-2,8,9
stromelysin MMP-310 and collagenase MMP-1.11 The MMP-1,
MMP-2 and MMP-9 are key regulators of collagens while
MMP-3 is considered as a main regulator of proteoglycans;
however, all these MMPs have broad substrate specificity
and participate in turnover of various ECM molecules. The
activity of MMPs is in turn regulated by the tissue inhibitors
of metalloproteinase (TIMPs), especially TIMP-1, which is
the most common and targets all active MMPs by non-
covalent binding in a 1:1 M ratio.12 In the airways of asth-
matic patients, TIMP-1 concentrations remain either
unchanged,9 even after allergen challenge,13 or are
enhanced,14e17 often even exceeding molar concentration
of MMPs.16e18
The reasons for the excessive ECM deposition in the
airways of asthmatic patients, and its consequences for
lung function and airway hyperreactivity, are uncertain.
Paradoxically, despite increased ECM accumulation,
enhanced concentration and activity of MMPs in the
asthmatic airways are generally considered as detri-
mental while TIMP-1 increase is seen as beneficial,
although a relationship between metalloproteolytic
activity in the airways and lung function of asthmatic
patients is not very well studied and results areinconsistent. The excessive ECM deposition could be
a result of an increased synthesis of ECM and/or attenu-
ated degradation of ECM. On the other hand, an enhanced
ECM degradation, especially when long-lasting, could via
defensive negative feedback result in an over-repair
where TIMP-1 might play a role.
To address these issues, the present study has investi-
gated the synthesis of procollagen I and total proteoglycans
by bronchial fibroblasts derived from biopsies obtained
from stable patients with mild-to-moderate asthma and
from age-matched healthy volunteers. The activity of the
MMP-9, MMP-3, MMP-2 and the production of MMP-1 and
TIMP-1 protein were also measured. We have then investi-
gated whether, and how, the synthesis of procollagen I and
of proteoglycans, as well as the activity of MMPs and the
production of TIMP-1, are related to patients’ lung func-
tion, measured as forced expiratory volume in 1 s and
expressed as percent of the predicted normal value
(FEV1%), and to airway hyperreactivity measured by meth-
acholine challenge.Materials and methods
Subjects
Eight patients (4 female and 4 male) suffering from asthma
and bronchial hyperresponsiveness were included in the
study. The patients were 25e55-year-old (25e39 years for 7
of 8 patients), non-smokers, with stable mild-to-moderate
asthma according to GINA guidelines (www.ginaasthma.
org), with confirmed airway hyperresponsiveness to meth-
acholine. A positive methacholine challenge test was
defined as a fall in FEV1  20% (PD20) on a cumulative dose
of methacholine <2000 mg, measured by a tidal volume
triggered technique (Automatic Provocation System, Erich
Jaeger GmbH). Of the 8 patients, 5 had an FEV1% predicted
of around 100% (including the oldest, 55-year-old man)
while 3 had values in the range of 62e67%; these 3 patients
also had the lowest PD20 values (<0.05 mg) (Table 1). All
patients were atopic, with skin prick tests confirming
sensitization towards perennial allergens, were free of
infections during the six weeks before bronchoscopy, and
were without corticosteroid treatment for six months prior
to the study.
Five age-matched control subjects (4 male and 1 female,
23e41 years of age) were included in the study. These were
non-asthmatic, non-allergic healthy volunteers without
respiratory symptoms and a negative methacholine chal-
lenge test (PD20 > 2000 mg).
The study was reviewed and approved by the Swedish
Research Ethical Committee (No LU339-00) and informed
consent was obtained from all participants.
Table 1 Baseline characteristics of patients with asthma
included in the study.
Sex Age (yr) FEV1 (% pred) PD20 (mg)
Pt 1 F 28 101 60
Pt 2 F 31 104 15
Pt 3 M 30 67 <0.05
Pt 4 F 25 95 20
Pt 5 M 35 62 <0.05
Pt 6 M 55 103 75
Pt 7 M 26 100 826
Pt 8 F 39 63 <0.05
Inclusion criteria for asthmatic patients are described in the
Methods. Definition of abbreviations: F Z female, M Z male,
PD20 (mg) to methacholine stimulation; % pred Z % predicted.
Matrix production by lung fibroblasts in asthma 1801Fibroblast outgrowth from biopsies
Bronchial biopsies were collected from the right lung of
each subject. Primary fibroblast-like cells were established
(as previously described in Ref.19) from the biopsies (one
for each subject) that did not show any differences in size,
vascular or muscle content. Briefly, the biopsies were cut
into small pieces and were allowed to adhere to cell-
culture plastic before the addition of Dulbecco’s Modified
Eagles’s Medium (DMEM) supplemented with 10% fetal
Clone III (Hyclone, UT), 1% L-glutamine, 0.5% gentamicin
and 5 mg/ml amphotericin. Biopsies were cultured until
outgrowth of cells with morphology typical of a fibroblast,
including a spindle-like shape and several protrusions.20,21
To ensure that true fibroblasts were cultured, markers for
fibroblasts and smooth muscle cells were used. The cells
were seeded in 4-well glass chamber slides (Nalge Nunc
International, Rochester, NY, USA) for 48 h, fixed with 4%
paraformaldehyde. Antibodies against vimentin in dilution
to 1 mg/ml (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), a-smooth muscle actin diluted 1:200 (Dako, Glostrup,
Denmark) and prolyl 4-hydroxylase in dilution to 1 mg/ml
(Acris Antibodies, Hiddenhausen, Germany) were used as
positive controls while a smooth muscle cell marker SM22 in
dilution to 2.5 mg/ml (Abcam, Cambridge, UK) was used as
a negative control. Corresponding Alexa fluorochrome
(Molecular Probes, Eugene, OR, USA) in 1% BSA and 5% goat
serum (Vector Laboratories Inc., Burlingame, CA, USA) were
used as secondary antibodies. Nuclei were visualized with
40-6-diamidino-2-phenylindole staining (Invitrogen Corp.,
Carlsbad, CA, USA). Isolated primary fibroblasts were used
in passages 4e6 for further experiments (cells were split
1:2 at expansions).
Study design
Experiments were performed in biopsy-derived bronchial
primary fibroblasts cultured in 6-well plates in Earle’s
minimal essential medium (SigmaeAldrich, Irvine, UK)
containing 10% (v/v) Fetal Clone III serum, (Hyclone, Logan,
UT, US), 1% L-glutamine, 0.5% gentamicin and 5 mg/ml
amphotericin at 37 C in a humidified 5% CO2 and 95%
atmosphere. Prior to the experiments, fibroblasts were
starved for 2 h in DMEM supplemented with 1% donor calfserum and 2 mM L-glutamine. Subsequently, cells were
incubated with 0.4% serum for 24 h in a MgSO4-poor DMEM
(Gibco BRL, Paisley, UK); the last 22 h in the presence of
50 mCi/ml [35S]-sulphate (PerkinElmer Life Science, Boston,
MA, USA). After incubation, the cell medium was collected
and the concentration of procollagen I carboxyterminal
propeptide (PICP), proteoglycans, MMP-1 and TIMP-1 and
the activity of MMP-9, MMP-3, MMP-2 were determined as
described below. All experiments with cells from each
individual were performed in homogenous, confluent
cultures, repeated two or three times, and mean value was
calculated for each patient.
Immunoassay for PICP, MMP-1 and TIMP-1
Concentrations of PICP in the culture media were measured
by enzyme-linked immunosorbent assay (ELISA) in accor-
dance with the manufacturer’s method (Takara Biochemi-
cals Co., Osaka, Japan). Concentrations of MMP-1 and TIMP-
1 (both free and complexed with MMPs) were analyzed by
ELISA (Amersham, GE Healthcare, Buckinghamshire, UK)
according to the manufacturer’s instructions. Data
obtained were related to the total protein content in the
corresponding cell layer using the BCA protein assay kit
(Pierce Chemical Co., Rockford, IL, USA).
Radiographic analysis of proteoglycans by anion-
exchange chromatography
Proteoglycans produced and released into the cell-culture
medium were isolated, purified and quantified by [35S]-
sulphate incorporation into the proteoglycan glycosamino-
glycan chains, as previously described.22 Briefly, collected
culture media were applied to anion-exchange DEAE
cellulose columns. After washing out the unincorporated
radioactive precursors, proteoglycans were eluted,
analyzed for [35S]-sulphate activity, quantified by liquid
scintillation counting and related to the total protein
content in the corresponding cell layer using the BCA
protein assay kit (Pierce Chemical Co., Rockford, IL, USA).
Zymography for MMP-9, MMP-2 and MMP-3
Presence and activity of proteolytic enzymes were analyzed
using Novex polyacrylamide zymogram gels and a prestained
molecular-weight marker BluePlus2 Prestained Standard
(Invitrogen, Stockholm, Sweden), as described elsewhere.23
Briefly, the gelatinase activity of MMP-9 and MMP-2 in the
collected and concentrated conditioned media was deter-
mined by preactivating equal volumes of each sample with
1mM 4-aminophenyl mercuric acetate (APMA) for 24e72 h (a
longer time period was required for MMP-9), and run on 10%
zymogram under non-denaturing conditions.
To determine the caseinolytic activity of MMP-3, all
samples were preactivatedwith 5 mg/ml trypsin for 30min at
37 C. The activation was terminated by 2 mM phenyl-
methylsulphon-fluoride and samples were run on 4e16%
zymogram (prestained Blue Casein) at 125 V for 2 h at 4 C.23
The gels were scanned and the gelatinolytic and casein-
olytic band areas of activity were quantified by densito-
metric analysis of an inverted display using transformation
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Figure 1 Procollagen I carboxyterminal propeptide (PICP)
synthesized by bronchial fibroblasts from 8 asthmatic patients.
PICP was measured by ELISA and normalized to the total
protein content in the corresponding cell layer (ng/mg protein).
A and B: Relation between PICP amount and patient FEV1%
predicted (A), and methacholine log PD20 (B). C: Relation
between PICP amount and total proteoglycan (PG) production
measured as [35S]-sulphate incorporation and normalized to
the total protein content in the corresponding cell layer (dpm/
mg protein, dpm Z disintegrations/min). Symbols represent
individual patients: Pt 1 Z open triangle, Pt 2 Z star, Pt
3 Z closed diamond, Pt 4 Z open diamond, Pt 5 Z closed
square, Pt 6Z open circle, Pt 7Z open square, Pt 8Z closed
triangle. Correlation analyses were performed using Pearson
correlation coefficients (r) with t-test of the regression.
1802 L. Todorova et al.tool program (BioRad Quantity One Software from Bio-Rad
Laboratories Inc., Hercules, CA, USA), and presented as
optical density (OD) related to the total protein content in
the corresponding cell layer using the BCA protein assay kit
(Pierce Chemical Co., Rockford, IL, USA).
Western immunoblotting of MMP-9, MMP-2 and
MMP-3
Identification of the different MMPs was confirmed by
Western blot. Briefly, equal amounts of preactivated
samples were subjected to 10% Tris-Glycine gels for MMP-2
and MMP-9, or 4e12% for MMP-3 (Invitrogen, Stockholm,
Sweden) and by electro-blotting transferred to a PVDF-P
Immobilon membrane (Millipore, Bedford, MA, USA).23 The
following primary antibodies were used: MMP-2 mouse anti-
human monoclonal IgG/K, MMP-9 rabbit anti-mouse
(Gelatinase B) polyclonal full length, and rabbit anti-MMP-3
(Chemicon, Temecula, CA, USA); all were diluted 1:1000 in
Tris-HCl, 150 mM NaCl, pH 7.5, 0.05% Tween with 1% BSA.
Polyclonal secondary antibodies used were rabbit anti-
mouse-HRP for MMP-2, swine anti-rabbit-HRP for MMP-9,
and rabbit anti-mouse-HRP for MMP-3; again all were
diluted 1:1000 (DakoCytomation, Glostrup, Denmark).
Bands were visualized after development with ECL Western
Blotting Detection Reagents (Amersham GE Healthcare,
Cardiff, UK).
Statistical analysis
Data are shown as values for individual subjects. An outlier
test was performed for each analysis to identify extreme
data points. Data points lying outside 10 times standard
deviation from mean value of the remaining points were
excluded from the analysis in question. The correlation
analysis was performed by testing the significance of Pearson
correlation coefficients (r) with t-test of the regression. The
mean values for asthmatic patients and healthy volunteers
were compared by unpaired, two-tailed independent t-test
for small samples. Differences were considered statistically
significant at p < 0.05. All analyses were performed using
Astute Software 1.5 (DDU Software, Leeds, UK).
Results
Production of PICP and proteoglycans
The synthesis of PICP and the total proteoglycans were on
average 2.3-fold and 1.4-fold higher, respectively, in
bronchial fibroblasts from asthmatic patients than from
healthy volunteers; however, this difference was not
statistically significant. The amount of PICP produced by
fibroblasts from asthmatic patients was negatively corre-
lated to patient FEV1% predicted (r Z 0.74, p Z 0.03;
Fig. 1A) and to methacholine log PD20 (r Z 0.71,
pZ 0.048; Fig. 1B). The negative associations between the
total amount of proteoglycans and patient FEV1% predicted
or log PD20 were not statistically significant (r Z 0.52,
p Z 0.19 and r Z 0.53, p Z 0.18, respectively). There
was a strong and positive correlation between the amounts
of PICP and proteoglycans both in fibroblasts from patients(r Z 0.93, p Z 0.001; Fig. 1C) and in those from healthy
volunteers (r Z 0.89, p Z 0.04).
MMP-9
Gelatin zymography showed enzymatic activity of MMP-9 in
fibroblast medium as an 82-kDa band (Fig. 2A), while the
92-kDa band of the pro-form and complexed forms around
200-kDa were often not visible. Very high MMP-9 activity
was obtained for one patient (Pt 8) who had a FEV1 of 63%
predicted value. This activity was 6e30 times higher than
those of the other asthmatic patients. This data point was
identified as an outlier e lying more than 10 times standard
Figure 2 Activity of MMP-9 in conditioned media of bronchial
fibroblasts from 7 asthmatic patients. Symbol for each indi-
vidual is shown as in Fig. 1; Pt 8 as an outlier is excluded. A:
Representative gelatin zymogram and Western blot (WB)
revealing both the presence and enzymatic activity of MMP-9
and MMP-2 in conditioned media. For MMP-9, the pro-form
enzyme was measured as a band at 92 kDa, the active enzyme
at 82 kDa, and high molecular complexes around 200 kDa. MMP-
9 activity at 82 kDa was quantified by densitometric analysis of
an inverted display and presented as optical density (OD)
normalized to the total protein content (mg) in the corre-
sponding cell layer. A and B: Relation between MMP-9 activity
and FEV1% predicted (A), and methacholine log PD20 (B).
Correlation analyses were performed using Pearson correlation
coefficients (r) with t-test of the regression.
Matrix production by lung fibroblasts in asthma 1803deviation (actually more than 14 times) from the mean
value of the remaining patients e and thus was excluded
from further MMP-9 analysis. MMP-9 activity was 1.6-fold
lower in fibroblasts from asthmatic patients than in those
from healthy volunteers but this difference did not reach
statistical significance (p Z 0.14).
There was a very strong and significant positive corre-
lation between fibroblast MMP-9 activity and patient FEV1%
predicted (rZ 0.97, pZ 0.0004; Fig. 2B) and methacholine
log PD20 (r Z 0.86, p Z 0.01; Fig. 2C). There was no
significant correlation between MMP-9 activity and amount
of PICP or proteoglycans in fibroblasts from patients
(r Z 0.52, p Z 0.23 and r Z 0.27, p Z 0.56, respec-
tively) or fibroblasts from healthy volunteers (r Z 0.46,
p Z 0.44 and r Z 0.43, p Z 0.47, respectively).
MMP-2
Gelatin zymography showed enzymatic activity of MMP-2 in
fibroblast medium as a 62-kDa band, a pro-form 72-kDa band
and high molecular complexes around 100 kDa (Fig. 2A). As
for MMP-9, fibroblasts from Pt 8 showed extremely high MMP-
2 activity that was 7e50 times higher than that of the other
asthmatic patients. This data point was identified as an
outlier (lyingmore than10 times standarddeviation, actually
more than 22 times, from the mean value of the remaining
patients) and thuswas excluded from furtherMMP-2analysis.
MMP-2 activity was similar in fibroblasts from asthmatic
patients and healthy volunteers and approximately 10 times
higher than MMP-9 activity.
There was a trend for a negative association between
MMP-2 activity and patient FEV1% predicted (r Z 0.60,
p Z 0.15; Fig. 3A) and methacholine log PD20 (r Z 0.69,
p Z 0.09; Fig. 3B). At the same time, the MMP-2 activity
was strongly and positively correlated with both the
amount of PICP (r Z 0.94, p Z 0.001; Fig. 3C) and
proteoglycans (r Z 0.89, p Z 0.007; Fig. 3D) in patients’
fibroblasts. In contrast, in fibroblasts from healthy volun-
teers there was no correlation between MMP-2 activity and
PICP or proteoglycan synthesis (r Z 0.39, p Z 0.51 and
r Z 0.10, p Z 0.89, respectively).
MMP-3
Casein zymography showed enzymatic activity of MMP-3 in
fibroblast medium as an active band at 45 kDa, pro-form
double band at 57/59 kDa and complexed form around
100 kDa (Fig. 4A). MMP-3 activity was 2.5-fold higher in
fibroblasts from asthmatic patients than in fibroblasts from
healthy volunteers, but this difference was not statistically
significant. There was a negative association, with border-
line statistical significance, between the MMP-3 activity and
patient FEV1% predicted (rZ 0.70, pZ 0.052; Fig. 4B) as
well asmethacholine log PD20 (rZ0.67, pZ 0.07; Fig. 4C).
The MMP-3 activity was strongly and positively correlated
with both the amount of PICP (rZ 0.89, pZ 0.003; Fig. 4D)
and proteoglycans (rZ 0.76, pZ 0.03; Fig. 4E) in patients’
fibroblasts. In contrast, in fibroblasts from healthy volun-
teers there was no correlation between MMP-3 activity and
PICP or proteoglycan production (r Z 0.47, p Z 0.42 and
rZ 0.16, pZ 0.79, respectively).MMP-1
MMP-1 protein levels were 3.7-fold higher in fibroblasts
from asthmatic patients than those from healthy volun-
teers, but this difference did not reach statistical
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Figure 3 Activity of MMP-2 in conditioned media of bronchial fibroblasts from 7 asthmatic patients. Symbol for each individual is
shown as in Fig. 1; Pt 8 as an outlier is excluded. Representative gelatin zymogram and Western blot (WB) are shown in Fig. 2A
where the MMP-2 pro-form enzyme was measured as a band at 72 kDa, the active enzyme at 62 kDa and high molecular complexes
around 100 kDa. MMP-2 activity at 62 kDa was quantified by densitometric analysis of an inverted display and presented as optical
density (OD) normalized to the total protein content (mg) in the corresponding cell. A and B: Relation between MMP-2 activity and
FEV1% predicted (A), and methacholine log PD20 (B). C and D: Relation between MMP-2 activity and procollagen I carboxyterminal
propeptide (PICP) amount (C), and total proteoglycan (PG) amount (D) (dpm Z disintegrations/min). Correlation analyses were
performed using Pearson correlation coefficients (r) with t-test of the regression.
1804 L. Todorova et al.significance. The MMP-1 amount produced by lung fibro-
blasts did not correlate with patient FEV1% predicted
(r Z 0.26, p Z 0.54) or methacholine log PD20 (r Z 0.52,
p Z 0.19). Furthermore, the MMP-1 level did not correlate
with the amount of PICP (r Z 0.06, p Z 0.88) or
proteoglycans (rZ 0.04, pZ 0.93) in patients’ fibroblasts
or fibroblasts from healthy volunteers (rZ 0.21, pZ 0.73
and r Z 0.34, p Z 0.58, respectively).
TIMP-1
The level of TIMP-1 protein was 1.5-fold higher in fibroblasts
from asthmatic patients than in those from healthy volun-
teers but this difference was not statistically significant.
There was no correlation between the amount of TIMP-1
produced by fibroblasts and patient FEV1% predicted
(rZ0.12, pZ 0.77) or methacholine log PD20 (rZ 0.29,
pZ 0.49). TIMP-1 levels correlated positively with the PICP
levels in fibroblasts from healthy volunteers (r Z 0.96,
pZ 0.008) and from asthmatic patients, although the latter
did not reach statistical significance (r Z 0.55, p Z 0.16;
Fig. 5A). TIMP-1 levels also correlated positively with the
total amount of proteoglycans both in fibroblasts from
healthy volunteers (r Z 0.84, p Z 0.07) and in those from
asthmatic patients (rZ 0.75, pZ 0.03; Fig. 5B).
There were no significant correlations between TIMP-1
and the activity of MMP-9 (r Z 0.16, p Z 0.72), MMP-2(rZ 0.63, pZ 0.13), MMP-3 (rZ 0.43, pZ 0.29) or MMP-1
protein (r Z 0.10, p Z 0.81) in patients’ fibroblasts or
fibroblasts from healthy volunteers (r Z 0.41, p Z 0.49
for MMP-9; r Z 0.46, p Z 0.43 for MMP-2; r Z 0.59,
p Z 0.30 for MMP-3; r Z 0.39, p Z 0.52 for MMP-1).
Discussion
The present study shows that a decrease in lung function and
an increase in airway hyperreactivity to methacholine in
patients with stable, mild-to-moderate asthma are associ-
atedwith increasedprocollagen I synthesis by biopsy-derived
bronchial fibroblasts. Production of both procollagen I and
proteoglycans was strongly and positively correlated with
the activity of MMP-2 and MMP-3 in asthmatic patients’
fibroblasts but not in fibroblasts from age-matched healthy
volunteers. In contrast, MMP-9 activity was not associated
with either procollagen I or proteoglycanproduction ineither
fibroblasts from asthmatic patients or healthy volunteers.
Furthermore, MMP-9 activity was strongly and positively
correlated with patient FEV1% predicted and methacholine
log PD20whereasMMP-2 andMMP-3 activitieswerenegatively
associated.
Increased levels of PICP have been reported in sputum of
asthmatic patients24 and also in the present study fibro-
blasts from asthmatic patients had more than 2-fold higher
levels of PICP compared to healthy volunteers, although
Figure 4 Activity of MMP-3 in conditioned media of bronchial fibroblasts from 8 asthmatic patients. Symbol for each individual is
shown as in Fig. 1. A: Representative casein zymogram and Western blot (WB) revealing both the presence and enzymatic activity of
MMP-3 in conditioned media. The pro-form enzyme was measured as a double band at 57/59 kDa, the active enzyme at 45 kDa, and
complex form around 100 kDa. MMP-3 activity at 45 kDa was quantified by densitometric analysis of an inverted display and
presented as optical density (OD) normalized to the total protein content (mg) in the corresponding cell layer. A and B: Relation
between MMP-3 activity and FEV1% predicted (A), and methacholine log PD20 (B). C and D: Relation between MMP-3 activity and
procollagen I carboxyterminal propeptide (PICP) amount (C), and total proteoglycan (PG) amount (D) (dpmZ disintegrations/min).
Correlation analyses were performed using Pearson correlation coefficients (r) with t-test of the regression.
Matrix production by lung fibroblasts in asthma 1805this difference did not reach statistical significance. PICP
levels reflect ongoing procollagen I synthesis and have been
proposed as a new marker of inflammation and airway
remodeling in asthma. Indeed, in the present study, PICP
produced by bronchial fibroblasts from asthmatic patients
were negatively correlated with patients’ lung function
assessed by FEV1 and with methacholine log PD20. This
finding supports the hypothesis that increased synthesis of
collagen I in the airways of asthmatic patients is clinically
important and plays a role in a decrease of lung function
and in an increase of airway hyperreactivity.
An increased deposition of specific proteoglycans in the
subepithelial layer in atopic, mild asthmatic patients was
reported in several studies25e27 and in the present study
therewas a trend for a higher production of the total amountof proteoglycans by bronchial fibroblasts from asthmatic
patients than those from healthy volunteers. Altered
proteoglycan deposition within the lungs may disturb the
fine-tuned ECMorganization and function, andmay influence
the deposition of other ECM molecules such as collagen and
fibronectin.28,29 In the present study, a negative association
between the total amount of proteoglycans produced by
bronchial fibroblasts from asthmatic patients and patients’
lung function, or methacholine log PD20, was not statistically
significant. Previous studies, however, have shown that
bronchial fibroblasts from subjects with hyper-responsive
airways produced more proteoglycans (total amount) than
those from healthy subjects,30 and that some specific
proteoglycans were correlated to low airway hyperreactivity
in asthmatic patients.26,30
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Figure 5 TIMP-1 protein production by bronchial fibroblasts
from 8 asthmatic patients. TIMP-1 was determined by ELISA and
normalized to the total protein content in the corresponding cell
layer (ng/mg protein). Symbol for each individual is shown as in
Fig. 1. A and B: Relation between TIMP-1 and procollagen I car-
boxyterminal propeptide (PICP) amount (A), and total proteo-
glycan (PG) amount (B) (dpm Z disintegrations/min).
Correlation analyses were performed using Pearson correlation
coefficients (r) with t-test of the regression.
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fibroblasts from asthmatic patients in the present study was
strongly and positively correlated with the activity of MMP-2
and MMP-3 whereas there were no such correlations in
fibroblasts from healthy volunteers. In contrast, MMP-9
activitywas not correlated to PICPor proteoglycan synthesis,
either in fibroblasts from asthmatic patients or in those from
healthy volunteers, despite MMP-9 sharing a broad spectrum
of substrate specificity with MMP-2. Nevertheless, MMP-9
does not degrade the two main collagen types, I and III,
deposited under subepithelial basement membrane and
submucosa in the airways of asthmatic patients, whileMMP-2
degrades them both, and MMP-3 degrades collagen type III.7
This seems to support the hypothesis that degradation of
collagens by MMP-2 and MMP-3 may lead via negative feed-
back mechanisms to increased synthesis and over-repair
manifested as an excessive collagen deposition. No signifi-
cant findings onMMP-1 in the present studymay be due to the
fact that only the level of MMP-1 protein but not its activity
was measured (zymography assay for MMP-1 was not
commercially available).
Since deposition of ECM is the net result of ECM synthesis
and degradation, an imbalance between various MMPs and
their main inhibitor TIMP-1 can influence ECM airway
remodeling in asthma.31 The TIMP-1 protects airway tissue
against activity of various MMPs but it may also preventproper repair and promote airway fibrosis. Indeed, sputum
TIMP-1 levels in mild stable asthmatic patients were shown
to be positively correlated with airway wall thickness while
MMP-9 levels were inversely correlated.18 Furthermore,
high levels of TIMP-1 tended to increase with asthma
severity,16 and TIMP-1 levels correlated negatively while
the MMP-9/TIMP-1 ratio correlated positively with FEV1%
predicted values,17,32 although no such correlations were
observed elsewhere.33 In the present study, there was
a trend for higher TIMP-1 levels in patients’ bronchial
fibroblasts than those from healthy volunteers; however,
they did not correlate with patients’ FEV1% predicted or
methacholine log PD20. On the other hand, TIMP-1 posi-
tively and strongly correlated with the production of
proteoglycans and procollagen I in fibroblasts from both
healthy and asthmatic individuals, although in asthmatic
patients’ fibroblasts the correlation with procollagen I
synthesis did not reach statistical significance. Thus, TIMP-1
may promote synthesis and deposition of proteoglycans and
procollagen I in the airways of both healthy individuals and
asthmatic patients although its role in enhanced collagen
deposition in asthmatic patients needs confirmation in
a larger study. Interestingly, although there were no
statistically significant correlations between TIMP-1 and the
activity of MMPs, negative associations between TIMP-1 and
activity of all MMPs investigated were seen in fibroblasts
from healthy volunteers while positive associations in
fibroblasts from asthmatic patients were observed. This
suggests a disturbed relationship between the activities of
MMPs and production of TIMP-1 by bronchial fibroblasts in
asthma patients and advocates for a scenario where
increased MMP activity results in over-production of TIMP-1
and subsequent over-repair of ECM.
In contrast to MMP-2 and MMP-3, the activity of MMP-9
produced by bronchial fibroblasts was not associated with
worsening of patients’ lung function and airway hyperreac-
tivity in the present study; on the contrary, the activity of
MMP-9 was positively and strongly correlated with patient
FEV1% predicted and methacholine log PD20. Based on this
finding, it is tempting to speculate that MMP-9 may have
abeneficial role inasthma.However, oneneeds tobecautious
because only 8 patients were investigated in this study,
including only 3 patients with low FEV1% predicted and low
methacholine log PD20. Therefore, additional studies with
more patients across a wider spectrum of asthma severities
are warranted to further evaluate this finding. Relatively few
studies have investigated a relationship between airwayMMP-
9 and lung function in asthma, and results are inconsistent.
Asthmatic patients showing positive immunostaining for MMP-
9 in subepithelial basement membranes had significantly
lower FEV1 values than asthmatic patients with negative
staining.34 Likewise, after allergen challenge in patients with
mildasthma, therewasapositivecorrelationbetweensputum
MMP-9 andamaximal fall in FEV1 both in theacutephase
13 and
in the late phase.35 On the other hand, in stable asthma of
varying severities, no correlation between sputumMMP-9 and
FEV1 values was observed.
17,32,33
In the present study, the activity of MMP-9 in bronchial
fibroblasts from each asthmatic patient was approximately
10-times lower than that of MMP-2. This is in contrast to
much higher levels of MMP-9 than MMP-2 being detected in
the airways of moderate-severe asthmatic patients, both
Matrix production by lung fibroblasts in asthma 1807during asthma attacks and remissions9,10 as well as in stable
asthma.16 On the other hand, during remissions in
moderate-severe asthma, MMP-9 levels were only slightly
higher than those in healthy subjects.9 Furthermore, in
patients with mild asthma only low MMP-9 levels were
detected,10 and MMP-9 levels or activity were often not
significantly different from control subjects [15, 34, this
study] but were increased after allergen challenge.13,15
These, and other findings (reviewed in Ref.36), suggest
that the major source of MMP-9 in acute/severe asthma are
inflammatory cells, while MMP-9 production by structural
cells, including bronchial fibroblasts, epithelial cells and
smooth muscle cells, may determine the MMP-9 levels
during stable disease.
Besides ECM degradation and remodeling, mechanisms
responsible for the effects of MMPs on lung function and
airway hyperreactivity in asthma may also involve other
effects crucial in asthma pathology. For example, one of
the major factors for increased airway hyperreactivity in
asthma is hyperplasia of airway smooth muscle cells, and
MMP-2 was shown to act as a permissive factor for prolif-
eration of these cells.37 Furthermore, it is well known that
MMPs also cleave non-ECM proteins and by that may acti-
vate or deactivate various cytokines, chemokines and their
cell receptors, modulating inflammation in the airways. In
this context, an important role of MMPs seems to be regu-
lation of chemokine gradients and thus traffic of inflam-
matory cells where, however, ECM degradation such as
proteolysis of proteoglycans, which bind and regulate
chemokine function, may be involved. Studies in MMP-9-
deficient mice strongly suggest that MMP-9 is a dominant
airway MMP that facilitates egression of inflammatory cells
from lung tissue into airway lumen and thus promotes
resolution of inflammation.38,39 MMP-9 also promotes
migration of regenerating epithelial cells implied in re-
epithelialization of the denuded airway mucosa and wound
closure after injury.40,41 A protective role of MMP-9 was
demonstrated in ozone-induced airway inflammation in
mice42 and, most recently, MMP-9 was shown to exert anti-
microbial function,43 which may be essential in prevention
of asthma exacerbations.
In conclusion, the present study shows that in patients
with stable mild-to-moderate asthma, increased synthesis of
procollagen I and activity of MMP-2 and MMP-3 in bronchial
fibroblasts may negatively affect patients’ lung function and
airway hyperreactivity. In contrast, MMP-9 activity was not
associated with increased procollagen I or proteoglycan
production, or worsening of patients’ lung function and
airway hyperreactivity. Since the synthesis of procollagen I
and proteoglycans by bronchial fibroblasts from asthmatic
patients positively and strongly correlated with the activity
of MMP-2 and MMP-3, while no such correlations were
observed in fibroblasts from healthy volunteers, an
enhanced synthesis and deposition of these ECM molecules
in the airways of asthmatic patients might be a result of
negative feedback from ECM degradation by these enzymes.Conflict of interest
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